Background: Referred hyperalgesia to a somatopically appropriate superficial site is a cardinal symptom of visceral inflammatory pain and has been demonstrated after turpentine-induced urinary bladder inflammation in the rat. The authors examined the effect of the endocannabinoids anandamide and palmitoylethanolamide on the referred hyperalgesia associated with this model.
THERE are fundamental clinical and physiologic differences between somatic and visceral pain. 1 A classical feature of visceral injury is referred pain, whereby the sufferer localizes the origin of the pain to a distant superficial structure (muscle or skin or both) innervated by the same spinal nerve as the affected viscus. It has been suggested that the sensory thresholds in the dermatome-myotome to which the pain is referred are reduced so that hyperalgesia is evident. Several models and theories of referred pain have been described. 1, 2 Current evidence favors a "central" convergence-facilitation hypothesis whereby the afferent barrage from the affected viscus initiates a focus of sensitization in dorsal horn neurons that receive a convergent input from both visceral and somatic structures. Persistence of central plastic changes described in this theory also explains the clinical phenomenon of continued referred hyperalgesia after cessation of the noxious stimulus. For example, a referred hyperalgesia exhibited by patients with a ureteric calculus persists long after removal of the calculus. 3 The neurotrophin nerve growth factor (NGF) plays a pivotal role in the development of visceral hyperalgesia, including referred hyperalgesia. 4, 5 The turpentine-inflamed rat urinary bladder is a well-established clinically relevant model of visceral hyperalgesia, and its features include (1) bladder hyper-reflexia, 4, 6 (2) sensitization of visceral primary afferents and segmental dorsal horn neurons, 7, 8 (3) recruitment of novel mechanoreceptive C fibers (silent afferents), 8 (4) induction of the early immediate gene c-fos in the spinal cord, 9 and (5) a referred (viscero-somatic) hyperalgesia. 5 These manifestations of turpentine-induced bladder inflammation are NGF-dependent, and, of particular importance to this study, the referred hyperalgesia to the rat hind paw associated with bladder inflammation is attenuated by NGF sequestration and is reproduced by intravesical administration of NGF. 5 Elements of the recently elucidated endogenous cannabinoid system appear to be able to attenuate the proinflammatory actions of NGF. 10 Cannabinoid activity at both the neuronal CB 1 receptor and the peripheral CB 2 receptor expressed on mast cells could contribute. We have previously shown that exogenous administration of the endocannabinoids anandamide (an endogenous CB 1 receptor agonist) and palmitoylethanolamide (a putative endogenous CB 2 receptor agonist) reduce bladder hyper-reflexia, one of the NGFdependent features of visceral hyperalgesia associated with this model. 6 Therefore, we investigated the effect of anandamide and palmitoylethanolamide on the referred hyperalgesia associated with turpentine inflammation of the rat urinary bladder. Furthermore, to ascertain the contribution of cannabinoid receptor subtypes to the effects of cannabinoids, CB 1 and CB 2 receptor antagonists were used.
Methods

Animal Maintenance and Instrumentation
All experiments conformed to British Home Office regulations (Home Office, Animals Procedures Section, London, United Kingdom). Experiments were performed on 50 female Wistar rats (mean weight, 219.5 g; range, 190 -260 g) that were housed according to national guidelines with a 12-h light-dark cycle and food and water ad libitum. Room temperature and humidity were controlled at a constant level during all experiments, which were performed at similar times in the light-dark cycle. For urethral canulation and bladder inflammation, anaesthesia was induced and maintained by inhalation of isoflurane (1-2%) in 50:50 oxygen and nitrous oxide. A sterile, lubricated nylon catheter (1.02-mm OD; Portex, Hythe, Kent, United Kingdom 200/300/030) was introduced into the bladder transurethrally. An unobstructed flow of clear urine was obtained before installation of turpentine.
Bladder Inflammation
Turpentine (0.5 ml 50% in olive oil) was instilled via the urethral catheter into the urinary bladder and left in situ for 1 h before removal by the same route. This provokes a sterile bladder inflammation within 1 h that persists for at least 48 h. 8 Twenty animals were randomly assigned to one of four groups (each group, n ϭ 5) that received either 25 mg/kg anandamide or equivalent volume of soya emulsion vehicle control or 25 mg/kg palmitoylethanolamide or equivalent volume of dimethyl sulphoxide (DMSO):saline (2:3) vehicle control by the intraperitoneal route. Two further groups (each n ϭ 5) received 10 mg/kg of either anandamide or palmitoylethanolamide also by the intraperitoneal route. A further 20 animals were randomized into four more groups (each group, n ϭ 5). One group received 25 mg/kg anandamide coadministered with 1 mg/kg of the CB 1 antagonist (SR141716A), and the other received the same dose of anandamide coadministered with 1 mg/kg of the CB 2 receptor antagonist (SR144528). Similarly, 25 mg/kg palmitoylethanolamide and 1 mg/kg of SR141716A or SR144528 were coadministered to the two remaining groups.
Thermal Sensory Threshold Assessment
Limb withdrawal latencies to a noxious thermal stimulus were measured to demonstrate thermal hyperalgesia. The plantar surface of the hind paw was used to assess alteration of somatic thresholds after visceral inflammation because its spinal innervation corresponds to an input at the L4 -L5 level 11 and shares a common root with vesical innervation (L5-L6, S1). 12, 13 The latency of limb withdrawal was measured using a Hargreave's device (Ugo Basile, Comerio, Varese, Italy). 14 This device applies a beam of infrared radiation at a wavelength of 50 nm onto the plantar surface of the paw. To prevent tissue damage, the maximum temperature delivered is 46°C, and the system cuts out automatically after 21.4 s. The system automatically cuts out when the animal withdraws its limb, and a latency in seconds is displayed. The animals were initially acclimatized to the testing environment (Plexiglas box, 23 ϫ 18 ϫ 14 cm, mounted on an infrared lucent dry glass pane) before baseline limb withdrawal latencies of both the hind and forepaws were measured. For these and all subsequent measurements, the mean of three tests was taken as the withdrawal latency. There was a delay of at least 1 min before retesting the same animal and 3 min between testing on the same paw. Contemporaneous measurement of both forelimb and hind limb withdrawal latencies provided an intraanimal internal control to negate any obfuscating factors affecting sensory thresholds such as systemic effects of inflammation or persistent effects of anesthesia. 5 Further latencies were measured at 2, 4, 6, 8, and 24 h after removal of turpentine from the bladder, and were all made by a single, blinded observer. After completion of the final test, the animals were humanely culled by cervical spine dislocation.
Materials
Anandamide and palmitoylethanolamide were purchased from Tocris Cookson (Bristol, Avon, United Kingdom). Anandamide was presented as a suspension in soya emulsion at a concentration of 10 mg/ml. Palmitoylethanolamide was dissolved in DMSO (Sigma, Poole, Dorset, United Kingdom) saline (2:3) to a concentration of 5 mg/ml. SR141716A was dissolved in DMSO saline (2:3) to a concentration of 1 mg/ml. SR144528 was also dissolved in DMSO and saline 2:3 to a concentration of 1 mg/ml.
Statistical Analysis
As previously reported, limb withdrawal latency was expressed as a percentage of the baseline value and as the difference between forelimb and hind limb. 5 This measure of ⌬Threshold was calculated by:
where H Thresh is the withdrawal latency of the hind limb, BH Thresh is the baseline withdrawal latency of the hind limb, F Thresh is the withdrawal latency of the forelimb, and BF Thresh is the baseline withdrawal latency of the forelimb. The mean ⌬Threshold was then plotted against time, with a negative difference indicating a relative hyperalgesia of the hind limb.
Changes in forelimb withdrawal latencies after treatment with endocannabinoids could potentially cause artefacts of ⌬Threshold. Therefore, to examine changes, forelimb withdrawal latencies were compared with baseline (one-way analysis of variance [ANOVA], post hoc Dunnett test).
To assess effects across the total time period, the area under the curve (AUC) for each of the ⌬Threshold against time curves for each animal in each group was calculated using the trapezium rule (Sigmaplot, Jandel Scientific Software, Version 4.01). Mean AUC values in each group were compared with control using ANOVA (post hoc Dunnett test; Sigmastat, Jandel Scientific, Version 2.0, San Rafael, CA).
Results
Referred Hyperalgesia after Turpentine Inflammation of the Rat Urinary Bladder
In the soya control group, a negative deflection consistent with a relative hyperalgesia of the hind limb was seen, and this effect is reduced by anandamide in a dose-related manner ( fig. 1A ). An example of derivation of ⌬Threshold for the soya control group is given in table 1. Treatment with anandamide did not alter forelimb latencies significantly (ANOVA, Dunnett, P Ͼ 0.05). The mean AUC (derived from ⌬⌻hreshold agonist time curves) of both the anandamide treatment groups were significantly different from control (ANOVA, Dunnett, P Ͻ 0.05; fig. 1B ). Similarly, plots of ⌬Threshold against time demonstrate a negative deflection in the DMSO: saline control group that is attenuated by both 25 and 10 mg/kg palmitoylethanolamide ( fig. 2A ). Forelimb latencies after administration of palmitoylethanolamide were not changed from baseline (ANOVA, Dunnett, P Ͼ 0.05). Corresponding mean AUC values demonstrated both treatment groups were significantly different from control (ANOVA, Dunnett, P Ͻ 0.05; fig. 2B ).
The effect of CB 1 and CB 2 receptor antagonists on the action of anandamide is shown in the ⌬Threshold against time plot ( fig. 3A) . Analysis of the corresponding AUCs reveals the action of anandamide to be mediated via CB 1 receptors (fig. 3B ). The AUC after coadministration of anandamide with the CB 1 receptor antagonist SR141716A is not significantly different from control (ANOVA, Dunnett, P Ͼ 0.05), whereas treatment with anandamide and the CB 2 receptor antagonist SR144528 results in an AUC significantly different from control (ANOVA, Dunnett, P Ͻ 0.05). Concomitant administration of antagonists with 25 mg/kg palmitoylethanolamide indicates an action predominantly via CB 2 receptor (figs. 4A and 4B). The AUC after coadministration of palmitoylethanolamide with SR141716A was significantly different from control (ANOVA, Dunnett, P Ͻ 0.05), whereas addition of SR144528 to 25 mg/kg palmi-toylethanolamide resulted in an AUC not significantly different from control (AVOVA, Dunnett, P Ͼ 0.05).
Discussion
These data confirm previous findings demonstrating the development of a thermal hyperalgesia referred to the plantar surface of the hind paw after turpentineinduced inflammation of the rat urinary bladder. 5 This was attenuated in a dose-dependent fashion by anandamide acting via the CB 1 receptor and by a CB 2 receptor-mediated effect of palmitoylethanolamide. The efficacy of these endocannabinoids in this model of visceral referred hyperalgesia suggests a role for cannabinoid agonists in the clinical management of referred hyperalgesia secondary to visceral inflammation. Moreover, the referred hyperalgesia of this model has been previously shown to be a NGF-dependent phenomenon, 5 and these data further highlight a cannabinoid role in the attenuation of NGF-driven inflammatory processes. 10
Nerve Growth Factor Is Pivotal in Plastic Changes after Visceral Inflammation
Nerve growth factor plays a pivotal role in this model of persistent visceral pain and in its clinical counterparts. First, not only is NGF protein and mRNA upregulated in animal models of bladder inflammation 15 and in certain types of human cystitis, 16 but the high-affinity receptor for NGF (tyrosine kinase A) is present on nearly all pelvic afferent neurons supplying the bladder. 17, 18 This particular capacity to respond to NGF suggests that NGF may be of special importance in visceral hyperalgesia. Second, sequestration of NGF by a tyrosine kinase A-immunoglobulin G fusion molecule attenuates manifestations of turpentine-induced inflammation of the urinary bladder, such as bladder hyper-reflexia and referred hyperalgesia. 4, 5 Finally, many of the features of turpentine-induced visceral hyperalgesia are reproduced by intravesicular administration of exogenous NGF, including bladder hyper-reflexia, 4 sensitization of visceral primary afferents, 7 and referred hyperalgesia. 5 
Plasticity and Pathways Involved in a Visceral Referred Hyperalgesia
Inflammation has profound effects on both the peripheral and central nociceptive processing of sensory infor-mation, which contributes to the spinal plasticity important in the development of referred hyperalgesia. For example, clinical human studies describe a renal calculus-induced referred hyperalgesia. Persistence of spinal plastic changes is demonstrated by continuing hyperalgesia even after stone destruction. 3 Other studies examining neurogenic plasma extravasation in appropriate areas of expected referred uterine pain after mustard oil-induced uterine inflammation also implicate mechanisms of referred hyperalgesia. 19 Afferent-afferent interaction in the spinal cord or a sympathetic reflex have been postulated, yet data suggest that both may be important. First, after bladder inflammation, the early immediate gene, c-fos, is expressed in several areas of the spinal cord (indicative of areas of visceral afferent input), including the superficial dorsal horn, the deep lateral dorsal horn and lamina X. 12 The latter two areas also contain preganglionic autonomic neurons and interneurons. 13 Incidentally, after nociceptive input from somatic structures, Fos is expressed in similar areas of the spinal cord as above, further evidence of convergence of visceral and somatic input. 20 Second, interneurons in the deep lateral dorsal horn of the spinal cord exhibit electrophysiologic viscero-somatic and viscerosympathetic convergence. 21 Third, part of the specific unpleasant sensation of visceral pain is a reflection of sympathetic activation and may be associated with autonomic symptoms such as sweating. 22 Modulation of autonomic processes (via interneurons) adds a theoretical facet to the convergence facilitation theory. 2 
Targets of CB 1 Receptor-Mediated Attenuation of Referred Hyperalgesia
Peripheral. Peripheral analgesic actions of cannabinoids have been demonstrated in somatic inflammatory pain models, 23 ,24 yet a specific peripheral site of visceral analgesia has not been clarified. 6 However, there is pharmacologic evidence that the CB 1 receptor is present in visceral structures, notably the urinary bladder, 25 and the gene encoding CB 1 is present in NGF-dependent primary afferent neurons that make up the majority of visceral primary afferent input. 26 Furthermore, not only are CB 1 receptor binding sites anterogradely transported out to the periphery, 27 but mRNA for the CB 1 receptor has been detected in the sensory cell bodies of the dorsal root ganglion. 28 CB 1 -mediated reduction of visceral affer-ent input presents a potent "upstream" site to attenuate the development of spinal plastic changes leading to referred hyperalgesia, but also presents a site of therapeutic action remote from the brain site responsible for unwanted psychotropic side effects.
Spinal. Electrophysiologic 29 and behavioral data 30 -32 support a spinal action of cannabinoid analgesia. Comparison of the structures associated with postulated mechanisms of referred hyperalgesia and recent detailed elucidation of CB 1 receptor expression in spinal cord may suggest a specific role for spinal cannabinoids in the modulation of visceral hyperalgesia. 33 First, the CB 1 receptor is found in the same spinal lamina (lamina I) as part of the central input of NGF-dependent class of peptidergic primary afferent neurons that terminate in laminae I and II outer. 33 Second, anandamide has been shown to inhibit the release of calcitonin gene-related peptide from the central terminals of NGF-dependent primary afferent nociceptors. 31 Third, CB 1 is expressed in the same spinal areas as convergent cells identified by Fos expression after both vesicular and somatic inflammation such as the superficial dorsal horn and lamina X. 13 Fourth, the CB 1 receptor is expressed mainly on neurons intrinsic to the spinal cord, and these interneurons are also present in areas analogous to the sympathetic intermediolateral nucleus and sacral parasympathetic nucleus. 33 Thus, agonist actions at the CB 1 receptor on spinal interneurons could inhibit the development of referred hyperalgesia (1) by attenuating cen-tral afferent input, (2) by direct modulation of convergent neurons, or (3) by inhibition of putative autonomic processes.
However, systemic administration of the endocannabinoids in this study can only lead to a speculative site of action, and given the existing evidence for supraspinal mechanisms of cannabinoid analgesia, 32,34 a supraspinal action of anandamide cannot be discounted.
Targets of CB 2 Receptor-Mediated Attenuation of Referred Hyperalgesia
Agonists at the CB 2 receptor expressed on mast cells also provide a separate mechanism by which palmitoylethanolamide could attenuate the NGF-mediated processes that contribute to referred hyperalgesia. NGF provokes mast cell degranulation, which releases a number of inflammatory mediators, including more NGF, effectively amplifying the NGF signal. Indeed, the mast cell has been recognized as a key player in certain clinical inflammatory conditions of the urinary bladder. 35 Facci et al. 36 demonstrated the efficacy of palmitoylethanolamide in the prevention of mast cell degranulation putatively via the peripheral CB 2 receptor. However, although in this study and others 23 the analgesic effects of palmitoylethanolamide are reversed by the CB 2 antagonist (SR144528), recent data questions whether palmitoylethanolamide binds to the CB 2 receptor with sufficient affinity to provoke agonist activity. 37 Even if palmitoylethanolamide did not itself act at the CB 2 receptor, it could act as a CB 2 -like receptor at which SR144528 also has antagonist activity. The label "CB 2 -like receptor" has been coined by several investigators to account for the non-CB 1 -non-CB 2 receptor-mediated actions of palmitoylethanolamide. 23, 38 Palmitoylethanolamide could also interfere with the breakdown of endogenous cannabinoids active at the CB 2 receptor in an "entourage effect." 39 These explanations could account for the observed attenuation of referred hyperalgesia by palmitoylethanolamide, which is reversed by SR144528.
The convergence facilitation theory proposes peripheral and spinal mechanisms thought to be important in the development of visceral referred hyperalgesia. Many of these processes involve NGF-driven elements. We have shown that anandamide (via CB 1 receptors) and palmitoylethanolamide (involving a CB 2 receptor-mediated process) attenuate this referred hyperalgesia. There is an anatomic basis for peripheral CB 1 -and CB 2 -mediated effects and a site for central CB 1 mediated actions both able to inhibit the processes necessary to incur a referred hyperalgesia. These data reinforce the analgesic action of cannabinoids, especially in the treatment of symptoms of visceral inflammatory hyperalgesia and propose cannabinoids, or compounds that inhibit degradation of endocannabinoids, as novel therapeutic strategies in visceral pain states. 
